Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Novo Nordisk A/S (NYSE:NVO) is among the cheap healthcare stocks to buy heading into 2026. On December 5, Kerry Holford, an analyst at Berenberg Bank, reaffirmed the ‘Buy’ rating on Novo Nordisk A/S ...

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

James Corden admitted he ditched Ozempic last year after it failed to curb his eating habits - but his lookalike sister, Ruth ...

Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by ...

Wave Life Sciences' $3.5B valuation reflects both pipeline risk and opportunity. Click here to find out why WVE stock is a Hold.

The rise of weight loss drugs such as Ozempic and Wegovy has changed the way Americans eat and shop, along with how major ...

Shortly after, Novo Nordisk’s CEO Mike Doustdar signaled the company is “all in” on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun ...